Prognostic indices of inflammatory markers, cognitive function and fatigue for survival in patients with localised colorectal cancer

Janette L Vardy, Haryana Mary Dhillon, Gregory R Pond, Corrinne Renton, Stephen J Clarke, Ian F Tannock, Janette L Vardy, Haryana Mary Dhillon, Gregory R Pond, Corrinne Renton, Stephen J Clarke, Ian F Tannock

Abstract

Background: Inflammation promotes the development of malignancy, while a variety of systemic markers of inflammation predict for worse cancer outcomes including recurrence and survival. Here, we evaluate the prognostic impact of cytokine concentrations, full blood count (FBC) differential ratios, cognitive function and fatigue on survival in patients with localised colorectal cancer (CRC).

Patients and methods: Data are from a prospective longitudinal study comparing cognitive function and fatigue in patients with CRC who did (n=173) and did not (n=116) receive adjuvant/neoadjuvant chemotherapy. Baseline blood results (prior to any chemotherapy) included cytokines and FBC from which neutrophil lymphocyte ratio, lymphocyte monocyte ratio, platelet lymphocyte ratio and platelet monocyte ratio were derived. Fatigue was measured with the Functional Assessment of Cancer Therapy-Fatigue subscale and cognitive function by a neuropsychological test battery. Kaplan-Meier methods were used to estimate disease-free survival (DFS) and overall survival (OS). Univariable and multivariable Cox regression analyses were performed to evaluate factors potentially prognostic of outcomes.

Results: At a median follow-up of 91.2 months, 227 subjects (79%) are still alive, and 212 (73%) have no evidence of a recurrence. Five-year OS and DFS are 86% (95% CI 81% to 90%) and 77% (95% CI 71% to 82%), respectively. None of the cytokines (interleukin (IL-6), IL-1 and tumour necrosis factor) or differential ratios of blood components, fatigue or cognitive function was statistically related to DFS or OS. Patient educational status (P=0.018), stage of disease (P=0.032), alanine transaminase (P=0.003), lactate dehydrogenase (P=0.008) and carcinoembryonic antigen (P=0.002) were significant as prognostic covariates of OS in univariable analyses, with similar results for DFS.

Conclusion: None of the a priori selected markers of inflammation, fatigue or cognitive function was associated with OS or DFS in this cohort of patients.

Trial registration number: NCT00188331, Post-results.

Keywords: colorectal cancer; cytokines; disease free survival; inflammation; neutrophil lymphocyte ratio; overall survival.

Conflict of interest statement

Competing interests: None declared.

References

    1. International WCRF. In cancer facts: World Cancer Research Fund International, 2017. .
    1. Society AC. In what are the survival rates for colorectal cancer, by stage? American Cancer Soceity, 2017. .
    1. Tan TT, Coussens LM. Humoral immunity, inflammation and cancer. Curr Opin Immunol 2007;19:209–16. 10.1016/j.coi.2007.01.001
    1. Dalgleish AG, O’Byrne KJ. Chronic immune activation and inflammation in the pathogenesis of AIDS and cancer. Adv Cancer Res 2002;84:231–76.
    1. O’Byrne KJ, Dalgleish AG. Chronic immune activation and inflammation as the cause of malignancy. Br J Cancer 2001;85:473–83. 10.1054/bjoc.2001.1943
    1. de Visser KE, Eichten A, Coussens LM. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 2006;6:24–37. 10.1038/nrc1782
    1. Galon J, Costes A, Sanchez-Cabo F, et al. . Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006;313:1960–4. 10.1126/science.1129139
    1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646–74. 10.1016/j.cell.2011.02.013
    1. Paik KY, Lee IK, Lee YS, et al. . Clinical implications of systemic inflammatory response markers as independent prognostic factors in colorectal cancer patients. Cancer Res Treat 2014;46:65–73. 10.4143/crt.2014.46.1.65
    1. Guo YH, Sun HF, Zhang YB, et al. . The clinical use of the platelet/lymphocyte ratio and lymphocyte/monocyte ratio as prognostic predictors in colorectal cancer: a meta-analysis. Oncotarget 2017;8:20024–20011. 10.18632/oncotarget.15311
    1. McMillan DC. The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer. Cancer Treat Rev 2013;39:534–40. 10.1016/j.ctrv.2012.08.003
    1. McMillan DC, Crozier JE, Canna K, et al. . Evaluation of an inflammation-based prognostic score (GPS) in patients undergoing resection for colon and rectal cancer. Int J Colorectal Dis 2007;22:881–6. 10.1007/s00384-006-0259-6
    1. Toiyama Y, Inoue Y, Saigusa S, et al. . C-reactive protein as predictor of recurrence in patients with rectal cancer undergoing chemoradiotherapy followed by surgery. Anticancer Res 2013;33:5065–74.
    1. Templeton AJ, McNamara MG, Šeruga B, et al. . Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst 2014;106 10.1093/jnci/dju124
    1. You J, Zhu GQ, Xie L, et al. . Preoperative platelet to lymphocyte ratio is a valuable prognostic biomarker in patients with colorectal cancer. Oncotarget 2016;7:25516–27. 10.18632/oncotarget.8334
    1. Ishizuka M, Nagata H, Takagi K, et al. . Combination of platelet count and neutrophil to lymphocyte ratio is a useful predictor of postoperative survival in patients with colorectal cancer. Br J Cancer 2013;109:401–7. 10.1038/bjc.2013.350
    1. Watt DG, Proctor MJ, Park JH, et al. . The Neutrophil-Platelet Score (NPS) predicts survival in primary operable colorectal cancer and a variety of common cancers. PLoS One 2015;10:e0142159 10.1371/journal.pone.0142159
    1. Chan JC, Chan DL, Diakos CI, et al. . The Lymphocyte-to-Monocyte ratio is a superior predictor of overall survival in comparison to established biomarkers of resectable colorectal cancer. Ann Surg 2017;265:539–46. 10.1097/SLA.0000000000001743
    1. Kwon HC, Kim SH, Oh SY, et al. . Clinical significance of preoperative neutrophil-lymphocyte versus platelet-lymphocyte ratio in patients with operable colorectal cancer. Biomarkers 2012;17:216–22. 10.3109/1354750X.2012.656705
    1. Chan JC, Diakos CI, Chan DL, et al. . A longitudinal investigation of inflammatory markers in colorectal cancer patients perioperatively demonstrates benefit in serial remeasurement. Ann Surg 2017:1 10.1097/SLA.0000000000002251
    1. Szkandera J, Pichler M, Absenger G, et al. . The elevated preoperative platelet to lymphocyte ratio predicts decreased time to recurrence in colon cancer patients. Am J Surg 2014;208:210–4. 10.1016/j.amjsurg.2013.10.030
    1. Vardy J, Dhillon HM, Pond GR, et al. . Cognitive function and fatigue after diagnosis of colorectal cancer. Ann Oncol 2014;25:2404–12. 10.1093/annonc/mdu448
    1. Vardy JL, Dhillon HM, Pond GR, et al. . Fatigue in people with localized colorectal cancer who do and do not receive chemotherapy: a longitudinal prospective study. Ann Oncol 2016;27:1761–7. 10.1093/annonc/mdw252
    1. Vardy JL, Dhillon HM, Pond GR, et al. . Cognitive function in patients with colorectal cancer who do and do not receive chemotherapy: a prospective, longitudinal, controlled study. J Clin Oncol 2015;33:4085–92. 10.1200/JCO.2015.63.0905
    1. Carey CL, Woods SP, Gonzalez R, et al. . Predictive validity of global deficit scores in detecting neuropsychological impairment in HIV infection. J Clin Exp Neuropsychol 2004;26:307–19. 10.1080/13803390490510031
    1. Yellen SB, Cella DF, Webster K, et al. . Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manage 1997;13:63–74. 10.1016/S0885-3924(96)00274-6
    1. Cella D. The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol 1997;34:13–19.
    1. Cella D, Lai JS, Chang CH, et al. . Fatigue in cancer patients compared with fatigue in the general United States population. Cancer 2002;94:528–38. 10.1002/cncr.10245
    1. Hsu T, Speers CH, Kennecke HF, et al. . The utility of abbreviated patient-reported outcomes for predicting survival in early stage colorectal cancer. Cancer 2017;123:1839–47. 10.1002/cncr.30511

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe